TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06581406: A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal

Sponsor: Replimune, Inc. · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 280 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$4,340,028

Rescue Site Savings

+$2,874,564

Unlock Full NCT06581406 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06581406 Rescue Dossier →